A new drug by Lycotec Ltd, United Kingdom, for the treatment of a bacterial infection has filed a patent application. The drug molecules are of food origin present in the Mediterranean diet and safe to consume. This is a first drug for the treatment of a bacterial infection that causes the development of cardiovascular disease (CVD) and atherosclerosis.
Researchers identified a number of viruses and bacteria in the atherosclerotic plaques in a patient with of a cardiovascular disease (CVD) during the last three decades. Infections due to these bacteria and viruses are the reasons for the worsening of the condition of atherosclerosis and cardiovascular diseases (CVD).
A study shows a reduction in anti-Chlamydia activity and blood markers of oxidative-inflammatory damage with the usage of this drug for four weeks in 85 percent of the patients with cardiovascular diseases. The manufacturer is going to present the drug and clinical trial results at the CBRS Conference in Charlotte, NC, in April 2017. Lycotec is currently looking for funding deal with others. Dr. Ivan Petyaev, the founder of Lycotec, is the inventor of this drug. Co-author of this study was Prof Nailya Zigangirova.
Patients with type 2 diabetes (T2D) in the United Kingdom (UK) can control blood sugar (glucose) levels with a new FDA approved qtern drug from AstraZeneca. It is a fixed-dose combination drug of 5 mg DPP-4 inhibitor (saxagliptin) and 10 mg SGLT2 inhibitor (dapagliflozin), to be used once in a day.
The drug was approved by the European Union in July 2016. Qtern drug improves glycemic control in patients with type 2 diabetes when.
The blood condition in an individual with high levels of triglycerides, fat phospholipids and LDL cholesterol is known as dyslipidemia. Dyslipidemia is associated with huge cost (price) to manage complications due to type 2 diabetes (T2D). The American Diabetes Association (ADA) says an American is spending about $13,700 to take care of diabetes.
Researchers from Kaiser Permanente, California, United States, says medical costs can be reduced with triglyceride lowering therapy in patients with type 2 diabetes (T2D). In an observational study on 184,000 patients with type 2 diabetes, researchers compared with triglyceride levels and medical costs before and after treatments to reduce high levels of cholesterol and triglyceride. The study shows.
The study was published in the American Journal of Cardiology.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.